SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-277914
Filing Date
2023-11-15
Accepted
2023-11-15 16:29:59
Documents
13
Period of Report
2023-11-15
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d941656d8k.htm   iXBRL 8-K 28805
2 EX-3.1 d941656dex31.htm EX-3.1 5436
  Complete submission text file 0001193125-23-277914.txt   165888

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20231115.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20231115_lab.xml EX-101.LAB 19484
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20231115_pre.xml EX-101.PRE 12151
7 EXTRACTED XBRL INSTANCE DOCUMENT d941656d8k_htm.xml XML 3675
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 231410967
SIC: 2836 Biological Products, (No Diagnostic Substances)